? CORE 3 The principal objective of the Biostatistics Core (Core 3) is to provide project investigators a centralized resource for biostatistics expertise. Statistical issues will be addressed at all levels of investigation: from the design of experiments and clinical trials, to the maintenance of data quality; and from conclusions based on formal hypothesis testing, to important leads discovered by thorough data exploration.
The specific aims of the Core are: 1.1. Collaborate with project investigators in the formulation of unambiguous hypotheses and hypothesis testing strategies, and in the design of experiments. Biostatistics collaboration will assist researchers at the design stage by: formulating biological and clinical questions as testable statistical hypotheses; devising efficient experimental designs and matching these with appropriate statistical models; determining sample sizes necessary to ensure high power; and strongly controlling. 1.2. Provide support for all projects with: formal hypothesis tests in experimental and clinical data that ensure strong conclusions; exploratory analyses that lead to further experiments, refined hypotheses, or discoveries; statistical modeling and sensitivity analyses of complex data; and visual displays of data that clarify conclusions and uncover leads. Core 3 statisticians have worked extensively with investigators to develop comprehensive analysis plans that distinguish between formal testing (which provides evidence for strong conclusions based on prior scientific knowledge/experimentation) and exploratory analyses (which do not allow for strong conclusions, but lay the groundwork for important discoveries). Core statisticians will employ the most robust methods for modeling and sensitivity analyses to ensure reliability of results. For all data, visual displays will be emphasized in order to reveal the reliability of conclusions and aid in the discovery of new leads. 1.3. Provide data management and integration services that ensure high integrity, security and investigator accessibility. Ensure statistical analysis consistency and transparency across projects, and have a centralized repository of all analysis procedures and results. To promote data integration across projects, Core 3 will have a centralized repository of all data that is secure and accessible to the investigators. Data will be cleaned, merged and de-identified. All missing and outlying data will be reported to investigators. Core 3 will ensure consistency of analysis plans and reports for the same data types across projects. 1.4. Develop new statistical methodologies to directly combat complex data or design problems that arise in projects and where current statistical methods do not apply. When faced with specific issues that arise in these projects where current statistical methods do not apply, Core 3 personnel will either adjust available methods or develop novel procedures to address the problems.

Public Health Relevance

? CORE 3 The Biostatistics Core will provide critical support for planning and design of experiments and studies, statistical analyses and display of data, and data management and integrity. This support is designed to ensure that studies yield reliable conclusions, resources are efficiently used, and exploratory analyses uncover important leads.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA163205-07
Application #
9787356
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
2019-09-01
Budget End
2020-08-31
Support Year
7
Fiscal Year
2019
Total Cost
Indirect Cost
Name
Brigham and Women's Hospital
Department
Type
DUNS #
030811269
City
Boston
State
MA
Country
United States
Zip Code
02115
Russell, Luke; Swanner, Jessica; Jaime-Ramirez, Alena Cristina et al. (2018) PTEN expression by an oncolytic herpesvirus directs T-cell mediated tumor clearance. Nat Commun 9:5006
Dai, Hong-Sheng; Caligiuri, Michael A (2018) Molecular Basis for the Recognition of Herpes Simplex Virus Type 1 Infection by Human Natural Killer Cells. Front Immunol 9:183
Chen, Luxi; Youssef, Youssef; Robinson, Cameron et al. (2018) CD56 Expression Marks Human Group 2 Innate Lymphoid Cell Divergence from a Shared NK Cell and Group 3 Innate Lymphoid Cell Developmental Pathway. Immunity 49:464-476.e4
Victor, Aaron R; Weigel, Christoph; Scoville, Steven D et al. (2018) Epigenetic and Posttranscriptional Regulation of CD16 Expression during Human NK Cell Development. J Immunol 200:565-572
Kim, Yangjin; Yoo, Ji Young; Lee, Tae Jin et al. (2018) Complex role of NK cells in regulation of oncolytic virus-bortezomib therapy. Proc Natl Acad Sci U S A 115:4927-4932
Sadahiro, Hirokazu; Kang, Kyung-Don; Gibson, Justin T et al. (2018) Activation of the Receptor Tyrosine Kinase AXL Regulates the Immune Microenvironment in Glioblastoma. Cancer Res 78:3002-3013
Scoville, Steven D; Nalin, Ansel P; Chen, Luxi et al. (2018) Human AML activates the aryl hydrocarbon receptor pathway to impair NK cell development and function. Blood 132:1792-1804
Chan, Wing Keung; Kang, Siwen; Youssef, Youssef et al. (2018) A CS1-NKG2D Bispecific Antibody Collectively Activates Cytolytic Immune Cells against Multiple Myeloma. Cancer Immunol Res 6:776-787
Nakashima, Hiroshi; Alayo, Quazim A; Penaloza-MacMaster, Pablo et al. (2018) Modeling tumor immunity of mouse glioblastoma by exhausted CD8+ T cells. Sci Rep 8:208
Marzulli, M; Mazzacurati, L; Zhang, M et al. (2018) A Novel Oncolytic Herpes Simplex Virus Design based on the Common Overexpression of microRNA-21 in Tumors. J Gene Ther 3:

Showing the most recent 10 out of 117 publications